| Lived experience submissions on new treatments and medicines, part of national working group looking at HTA reform, part of industry campaign to improve timeliness of HTA approval [Australia]. | Atemwege
> Lungenerkrankungen | Regulatorische Partnerschaft
> Teilnahme an Health Technology Assessment (HTA) und Erstattungsprüfungen | Over 100,000 | National | Regularly | 119011106646 |
| Work with PBAC [Pharmaceutical Benefits Advisory Committee], HTA [Health Technology Assessment], TGA [Therapeutic Goods Administration], and MSAC [Medical Services Advisory Committee], as well as patient groups and Medicines Australia Australia to advocate for access and equity for treatments and care. | Neuromuskulär
> Muskeldystrophie | Regulatorische Partnerschaft
> Teilnahme an Health Technology Assessment (HTA) und Erstattungsprüfungen | 1.000 | National | Regularly | 119021570524 |
| We support and advocate for enhancement of the involvement of patients/carers in Health Technology. We have been involved in the Co design group Enhancing Consumer involvement in Australian Health technology assessment and in the HTA Review process. | Krebs
> Krebs: die meisten Arten | Regulatorische Partnerschaft
> Teilnahme an Health Technology Assessment (HTA) und Erstattungsprüfungen | We do not communicate with patients directly | Regional | Sometimes | 119031444677 |
| Consumer feedback to PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], government consultations, and other organisations on behalf of those with kidney disease. | Niere
> Nierenerkrankungen | Regulatorische Partnerschaft
> Teilnahme an Health Technology Assessment (HTA) und Erstattungsprüfungen | Do not know | National | Regularly | 119051003447 |
| We provide public comment to the Pharmaceutical Benefits Advisory Committee [PBAC] for the reimbursement of medicines relating to asthma, including some vaccines. | Atemwege
> Asthma | Regulatorische Partnerschaft
> Teilnahme an Health Technology Assessment (HTA) und Erstattungsprüfungen | Over 100,000 | National | Regularly | 119051065145 |
| PBAC [Pharmaceutical Benefits Advisory Committee] comments. | Haut
> Atopische Dermatitis/Ekzem | Regulatorische Partnerschaft
> Teilnahme an Health Technology Assessment (HTA) und Erstattungsprüfungen | Over 100,000 | National | Regularly | 119051082840 |
| HTA [Health Technology Assessment] — lived experience. | Atemwege
> Lungenerkrankungen | Regulatorische Partnerschaft
> Teilnahme an Health Technology Assessment (HTA) und Erstattungsprüfungen | Over 100,000 | National | Regularly | 119051865995 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | Selten
> Seltene Erkrankungen: genetisch | Regulatorische Partnerschaft
> Teilnahme an Health Technology Assessment (HTA) und Erstattungsprüfungen | 1.000 | National | Sometimes | 119054286714 |
| Involved in government [Australia] policy reviews - HTA review and Chronic Disease - submit responses to TGA [Therapeutic Goods Administration], MSAC [Medical Services Advisory Committee], and PBAC [Pharmaceutical Benefits Advisory Committee] in relation to sponsor requests. | Gastrointestinal
> IBD | Regulatorische Partnerschaft
> Teilnahme an Health Technology Assessment (HTA) und Erstattungsprüfungen | Over 100,000 | National | Regularly | 119058351283 |
| PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], PL [Prostheses List]. | Kardiovaskulär
> Herz-Kreislauf- & Herzerkrankungen | Regulatorische Partnerschaft
> Teilnahme an Health Technology Assessment (HTA) und Erstattungsprüfungen | Do not know | International | Regularly | 119061299937 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. A recent example of our work representing patient interests to regulators that are responsible for deciding drug pricing was recent correspondence we issued to the Australian Pharmaceutical Benefits Advisory Committee, requesting that a drug for the treatment of schizophrenia be listed on the Pharmaceutical Benefits Scheme. In this correspondence, we directly represented the views of patients and family and carers. | Psychische Gesundheit
> Psychische Gesundheit: die meisten Erkrankungen | Regulatorische Partnerschaft
> Teilnahme an Health Technology Assessment (HTA) und Erstattungsprüfungen | 10.000 | National | Sometimes | 119074282308 |
| We provide public comment to the Pharmaceutical Benefits Advisory Committee for the reimbursement of medicines relating to asthma, including some vaccines. We write and support submissions to the Therapeutic Goods Administration for changes to medicines. Asthma Australia will lobby government if a change that is made is not in the best interest of people with asthma. | Atemwege
> Asthma | Regulatorische Partnerschaft
> Beitrag zu Zulassungsanträgen leisten | Over 100,000 | National | Regularly | 119051065145 |
| Work with PBAC [Pharmaceutical Benefits Advisory Committee], HTA [Health Technology Assessment], TGA [Therapeutic Goods Administration], and MSAC [Medical Services Advisory Committee], as well as patient groups and Medicines Australia Australia to advocate for access and equity for treatments and care. | Neuromuskulär
> Muskeldystrophie | Regulatorische Partnerschaft
> Teilnahme an/Durchführung von Treffen mit politischen Entscheidungsträgern/Regulierungsbehörden | 1.000 | National | Regularly | 119021570524 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. | Psychische Gesundheit
> Psychische Gesundheit: die meisten Erkrankungen | Regulatorische Partnerschaft
> Mit anderen Gesundheitsfürsprechern | 10.000 | National | Sometimes | 119074282308 |
| Regular advocacy and lobbying to all levels of government on new and current diabetes medications and technology. | Endokrin
> Diabetes (Typ 1 und Typ 2) | Einfluss auf Politik und Gesetzgebung
> Gesundheitspolitik und Gesetzgebung beeinflussen | Over 100,000 | National | Regularly | 119023443093 |
| We provide public comment to the Pharmaceutical Benefits Advisory Committee for the reimbursement of medicines relating to asthma, including some vaccines. We write and support submissions to the Therapeutic Goods Administration for changes to medicines. Asthma Australia will lobby government if a change that is made is not in the best interest of people with asthma. | Atemwege
> Asthma | Einfluss auf Politik und Gesetzgebung
> Gesundheitspolitik und Gesetzgebung beeinflussen | Over 100,000 | National | Regularly | 119051065145 |
| Involved in government [Australia] policy reviews - HTA review and Chronic Disease - submit responses to TGA [Therapeutic Goods Administration], MSAC [Medical Services Advisory Committee], and PBAC [Pharmaceutical Benefits Advisory Committee] in relation to sponsor requests. | Gastrointestinal
> IBD | Einfluss auf Politik und Gesetzgebung
> Gesundheitspolitik und Gesetzgebung beeinflussen | Over 100,000 | National | Regularly | 119058351283 |
| Where possible, we add our advocacy voice to decision-makers. | Neuromuskulär
> Muskeldystrophie | Einfluss auf Politik und Gesetzgebung
> Gesundheitspolitik und Gesetzgebung beeinflussen | 1.000 | National | Rarely | 119070072574 |
| Consumer feedback to PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], government consultations, and other organisations on behalf of those with kidney disease. | Niere
> Nierenerkrankungen | Einfluss auf Politik und Gesetzgebung
> An öffentlichen Anhörungen und Konsultationen teilnehmen | Do not know | National | Regularly | 119051003447 |
| Public submissions. | Medizinische Forschung
> Medizinische Forschung | Einfluss auf Politik und Gesetzgebung
> An öffentlichen Anhörungen und Konsultationen teilnehmen | 100 | National | Sometimes | 119075599019 |
| Pre-Budget Submissions, Advocacy activities, Meetings. | Rheumatisch
> Rheumatische Erkrankungen: die meisten Arten | Einfluss auf Politik und Gesetzgebung
> Parlamentarier und politische Führungspersönlichkeiten mobilisieren | Over 100,000 | National | Regularly | 119017682842 |
| Weight loss drugs, general medicine costs. | Patientenvertretung
> Patientenrechte | Preisgestaltung und Erschwinglichkeitsförderung
> Für faire Medikamentenpreise eintreten | 100.000 | National | Sometimes | 119055318270 |
| Involved in government [Australia] policy reviews - HTA review and Chronic Disease - submit responses to TGA [Therapeutic Goods Administration], MSAC [Medical Services Advisory Committee], and PBAC [Pharmaceutical Benefits Advisory Committee] in relation to sponsor requests. | Gastrointestinal
> IBD | Preisgestaltung und Erschwinglichkeitsförderung
> Für faire Medikamentenpreise eintreten | Over 100,000 | National | Regularly | 119058351283 |
| Pricing. | Rheumatisch
> Lupus | Preisgestaltung und Erschwinglichkeitsförderung
> Für faire Medikamentenpreise eintreten | 5.000 | International | Regularly | 119058972997 |
| Through an HTA [Health Technology Assessment] implementation review, direct advocacy around drug access and pricing, part of roundtables to more effectively advocate patient interests for change. | Neurologisch
> Neurologisch: Sonstiges | Preisgestaltung und Erschwinglichkeitsförderung
> Für faire Medikamentenpreise eintreten | We do not communicate with patients directly | National | Regularly | 119069368666 |
| We will sometimes complete Consumer Comments for the Pharmaceutical Benefits Advisory Committee if we feel that an immunization should be federally funded on the National Immunization Program. | Ansteckend
> Immunisierung | Preisgestaltung und Erschwinglichkeitsförderung
> Befürwortung der Aufnahme des Produkts in Erstattungslisten/nationale Arzneimittelverzeichnisse | Over 100,000 | National | Sometimes | 119022383972 |
| Access to Palovarotene [to reduce the formation of abnomal bone tissue in people with It is indicated for patients with the ultra-rare genetic disorder Fibrodysplasia Ossificans Progressiva (FOP)] via the PBS [Pharmaceutical Benefits Scheme] listing. | Knochen
> Fibrodysplasia ossificans progressiva (FOP) | Preisgestaltung und Erschwinglichkeitsförderung
> Befürwortung der Aufnahme des Produkts in Erstattungslisten/nationale Arzneimittelverzeichnisse | 100 | National | Rarely | 119044789085 |
| Australia's PBS [Pharmaceutical Benefits Scheme] listings as an example. | Niere
> Nierenerkrankungen | Preisgestaltung und Erschwinglichkeitsförderung
> Befürwortung der Aufnahme des Produkts in Erstattungslisten/nationale Arzneimittelverzeichnisse | 5.000 | National | Regularly | 119050789619 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | Selten
> Seltene Erkrankungen: genetisch | Preisgestaltung und Erschwinglichkeitsförderung
> Befürwortung der Aufnahme des Produkts in Erstattungslisten/nationale Arzneimittelverzeichnisse | 1.000 | National | Sometimes | 119054286714 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. A recent example of our work representing patient interests to regulators that are responsible for deciding drug pricing was recent correspondence we issued to the Australian Pharmaceutical Benefits Advisory Committee, requesting that a drug for the treatment of schizophrenia be listed on the Pharmaceutical Benefits Scheme. In this correspondence, we directly represented the views of patients and family and carers. | Psychische Gesundheit
> Psychische Gesundheit: die meisten Erkrankungen | Preisgestaltung und Erschwinglichkeitsförderung
> Befürwortung der Aufnahme des Produkts in Erstattungslisten/nationale Arzneimittelverzeichnisse | 10.000 | National | Sometimes | 119074282308 |
| Work with PBAC [Pharmaceutical Benefits Advisory Committee], HTA [Health Technology Assessment], TGA [Therapeutic Goods Administration], and MSAC [Medical Services Advisory Committee], as well as patient groups and Medicines Australia Australia to advocate for access and equity for treatments and care. | Neuromuskulär
> Muskeldystrophie | Verbesserung der Zugangswege
> Gleichberechtigten Zugang zu Medikamenten/Gesundheitsversorgung fördern | 1.000 | National | Regularly | 119021570524 |
| Weight loss drugs, general medicine costs. | Patientenvertretung
> Patientenrechte | Verbesserung der Zugangswege
> Gleichberechtigten Zugang zu Medikamenten/Gesundheitsversorgung fördern | 100.000 | National | Sometimes | 119055318270 |
| Regulations and restrictions regarding prescribing of antivirals for COVID to our patient cohort [neurological conditions]. | Neurologisch
> Neurologisch: Sonstiges | Verbesserung der Zugangswege
> Gleichberechtigten Zugang zu Medikamenten/Gesundheitsversorgung fördern | 5.000 | National | Rarely | 119056702514 |
| PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], PL [Prostheses List]. | Kardiovaskulär
> Herz-Kreislauf- & Herzerkrankungen | Verbesserung der Zugangswege
> Gleichberechtigten Zugang zu Medikamenten/Gesundheitsversorgung fördern | Do not know | International | Regularly | 119061299937 |
| Through an HTA [Health Technology Assessment] implementation review, direct advocacy around drug access and pricing, part of roundtables to more effectively advocate patient interests for change. | Neurologisch
> Neurologisch: Sonstiges | Verbesserung der Zugangswege
> Gleichberechtigten Zugang zu Medikamenten/Gesundheitsversorgung fördern | We do not communicate with patients directly | National | Regularly | 119069368666 |
| Through an HTA [Health Technology Assessment] implementation review. | Neurologisch
> Neurologisch: Sonstiges | Verbesserung der Zugangswege
> Gleichberechtigten Zugang zu Medikamenten/Gesundheitsversorgung fördern | We do not communicate with patients directly | National | Regularly | 119069368666 |
| We will sometimes complete Consumer Comments for the Pharmaceutical Benefits Advisory Committee if we feel that an immunization should be federally funded on the National Immunization Program. | Ansteckend
> Immunisierung | Verbesserung der Zugangswege
> Für einen breiteren Impfstoffzugang eintreten | Over 100,000 | National | Sometimes | 119022383972 |
| Access to Palovarotene [to reduce the formation of abnomal bone tissue in people with It is indicated for patients with the ultra-rare genetic disorder Fibrodysplasia Ossificans Progressiva (FOP)] via the PBS [Pharmaceutical Benefits Scheme] listing. | Knochen
> Fibrodysplasia ossificans progressiva (FOP) | Verbesserung der Zugangswege
> Verbesserung des Zugangs zu seltenen/extrem seltenen Therapien | 100 | National | Rarely | 119044789085 |
| Consumer feedback to PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], government consultations, and other organisations on behalf of those with kidney disease. | Niere
> Nierenerkrankungen | Evidenzbasierter Patientenbeitrag
> Nutzen Sie Patienteneinblicke, um Entscheidungen zu treffen | Do not know | National | Regularly | 119051003447 |
| Lived experience submissions on new treatments and medicines, part of national working group looking at HTA reform, part of industry campaign to improve timeliness of HTA approval [Australia]. | Atemwege
> Lungenerkrankungen | Evidenzbasierter Patientenbeitrag
> Nutzen Sie Patientengeschichten und Erfahrungsberichte aus erster Hand | Over 100,000 | National | Regularly | 119011106646 |
| We support and advocate for enhancement of the involvement of patients/carers in Health Technology. We have been involved in the Co design group Enhancing Consumer involvement in Australian Health technology assessment and in the HTA Review process. | Krebs
> Krebs: die meisten Arten | Evidenzbasierter Patientenbeitrag
> Nutzen Sie Patientengeschichten und Erfahrungsberichte aus erster Hand | We do not communicate with patients directly | Regional | Sometimes | 119031444677 |
| HTA [Health Technology Assessment] — lived experience. | Atemwege
> Lungenerkrankungen | Evidenzbasierter Patientenbeitrag
> Nutzen Sie Patientengeschichten und Erfahrungsberichte aus erster Hand | Over 100,000 | National | Regularly | 119051865995 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. A recent example of our work representing patient interests to regulators that are responsible for deciding drug pricing was recent correspondence we issued to the Australian Pharmaceutical Benefits Advisory Committee, requesting that a drug for the treatment of schizophrenia be listed on the Pharmaceutical Benefits Scheme. In this correspondence, we directly represented the views of patients and family and carers. | Psychische Gesundheit
> Psychische Gesundheit: die meisten Erkrankungen | Evidenzbasierter Patientenbeitrag
> Nutzen Sie Patientengeschichten und Erfahrungsberichte aus erster Hand | 10.000 | National | Sometimes | 119074282308 |
| Pricing, clinical trials. | Rheumatisch
> Lupus | Diagnose und Medikamentenlieferung
> Zusammenarbeit bei der Gestaltung klinischer Studien | 5.000 | International | Regularly | 119058972997 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | Selten
> Seltene Erkrankungen: genetisch | Diagnose und Medikamentenlieferung
> Screening und Früherkennung unterstützen | 1.000 | National | Sometimes | 119054286714 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | Selten
> Seltene Erkrankungen: genetisch | Institutionelle Governance
> Sicherstellen der Vertretung in staatlichen Beratungsgremien | 1.000 | National | Sometimes | 119054286714 |
| Preterm Infants Parents Association [PIPA] has representatives on numerous hospital and Queensland Health Department committees. | Kindergesundheit
> Neonatal | Institutionelle Governance
> Sicherstellen der Vertretung in staatlichen Beratungsgremien | 5.000 | Regional | Regularly | 119074312093 |
| Through an HTA [Health Technology Assessment] implementation review, direct advocacy around drug access and pricing, part of roundtables to more effectively advocate patient interests for change. | Neurologisch
> Neurologisch: Sonstiges | Institutionelle Governance
> Effektiv in Netzwerken mit mehreren Interessengruppen arbeiten | We do not communicate with patients directly | National | Regularly | 119069368666 |
Interaktionen
Aktionen & Interessenvertretung
14 Erwähnungen
